InsiderClue
Insiders · Profile

PAUL STEVEN M

Director at Rapport Therapeutics · Director at ALNYLAM PHARMACEUTICALS · President and CEO at Voyager Therapeutics · and 1 more. Filing since 20 Oct 2006. CIK 0001237564

RAPP Rapport Therapeutics, Inc. Director · 1 trade ALNY ALNYLAM PHARMACEUTICALS, INC. Director · 4 trades VYGR Voyager Therapeutics, Inc. President and CEO · 1 trade LLY Lilly (Eli) EVP, Science and Technology · 5 trades
Company
Date
Role
Action
Shares
Amount
Of holding
RAPP Rapport Therapeutics, Inc.
12 Sep 2025
Director
Bought
41,666
$1.03M
opened
ALNY ALNYLAM PHARMACEUTICALS, INC.
1 Apr 2022
Director
Sold, plan not stated
15,000
$2.56M
93.8%
ALNY ALNYLAM PHARMACEUTICALS, INC.
18 Dec 2020
Director
Sold, plan not stated
15,000
$2.10M
93.8%
ALNY ALNYLAM PHARMACEUTICALS, INC.
10 Feb 2020
Director
Sold, plan not stated
30,000
$3.90M
96.8%
VYGR Voyager Therapeutics, Inc.
14 Jan 2016
President and CEO
Bought
10,000
$140.69K
1.2%
ALNY ALNYLAM PHARMACEUTICALS, INC.
26 Jan 2015
Director
Bought
1,000
$95.00K
opened
LLY Lilly (Eli)
4 Feb 2008
EVP, Science and Technology
Sold, plan not stated
19,822
$1.02M
28.3%
LLY Lilly (Eli)
12 Mar 2007
EVP, Science and Technology
Sold, plan not stated
7,289
$381.87K
87.2%
LLY Lilly (Eli)
12 Feb 2007
EVP, Science and Technology
Sold, plan not stated
7,290
$396.43K
46.6%
LLY Lilly (Eli)
8 Feb 2007
EVP, Science and Technology
Sold, plan not stated
10,092
$548.23K
15.6%
LLY Lilly (Eli)
20 Oct 2006
EVP, Science and Technology
Sold, plan not stated
4,836
$275.22K
81.9%
11 decisions on file.